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Abstract: 
Despite evidence of ethnic differences in substance use patterns among adolescents in 
community samples, clinical studies have not found ethnic differences in posttreatment 
outcomes. Prior clinical studies have been limited by small samples, focus on broad treatment 
modalities, and lack of consideration of important covariates. We investigated ethnic differences 
in substance use frequency and problems in a large sample of White (60%), African American 
(12%), and Latino (28%) adolescents prior to and following an evidence-based treatment. 
Participants included 4,502 adolescents (29% female), with ages 13–18 years, who received 
Motivational Enhancement Therapy/Cognitive Behavior Therapy 5 Sessions. At baseline, 
African American adolescents demonstrated less frequent use, fewer problems, and less 
comorbidity than Whites or Latinos. Consistent with prior research, there were no ethnic 
differences in substance use outcomes among assessment completers (71%) when controlling for 
baseline differences. However, African Americans, older adolescents, and males were less likely 
to complete the posttreatment assessment. Implications for clinical service and effectiveness 
research are discussed. 
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Article: 
1. Introduction 
A critical issue in developing and delivering effective treatment for adolescent substance abuse 
(ASA) is to establish whether evidence-based interventions are effective across racial and ethnic 
groups (U.S. Department of Health and Human Services, 2001). Understanding the applicability 
of ASA interventions for African Americans and Latinos is particularly important, considering 
that these groups comprise more than one quarter of the American population (Humes, Jones, & 
Ramirez, 2011). Examining whether treatment is effective across White, African American, and 
Latino adolescents requires addressing several specific questions. First, do African American and 
Latino youth differ from White youth when they enter treatment? Second, does treatment lead to 
significantly different outcomes for White versus African American and Latino youth? Third, are 
differences in outcome attributable to baseline differences among the groups? In this study, we 
address these questions to evaluate the applicability of a brief evidence-based, outpatient 
intervention for ASA within a treatment dissemination project. For parsimony, we refer to 
differences among White, African American, and Latino youth as ethnic differences rather than 
racial/ethnic differences (Strada, Donohue, & Lefforge, 2006). 
Hypotheses regarding ethnic differences in ASA prior to treatment can be based on community 
studies. In community samples, White youth often report higher levels of substance use and 
higher rates of diagnosed substance use disorders than do African American youth, whereas 
White and Latino teens report more similar patterns of use (Blum et al., 2000, Griffin et al., 
2000, Johnston et al., 2008, Kilpatrick et al., 2000, Roberts et al., 2006 and Wallace et al., 2002). 
However, some studies suggest that African Americans experience more social problems and 
internalizing distress associated with alcohol use than Whites (Godette et al., 2006 and Maag and 
Irvin, 2005). 
 
Regarding posttreatment outcome, relatively few clinical studies have reported on ethnic 
differences. Rounds-Bryant and Staab (2001) compared the substance abuse and mental health 
outcomes of White, African American, and Latino youth in the large, multisite Drug Abuse 
Treatment Outcome Study for Adolescents (DATOS-A; Hser et al., 2001). At baseline, rates of 
alcohol and marijuana use were similar across the three groups, but Whites were more likely to 
meet diagnostic criteria for substance dependence and more likely to have comorbid depression. 
Despite these differences, all three ethnic groups experienced similar reductions in substance use 
after treatment. A limitation of this study was that it evaluated broad treatment modalities (e.g., 
outpatient, residential, short-term inpatient) rather than specific evidence-based interventions. 
 
In a recent review of controlled ASA treatment studies, Strada et al. (2006) similarly found a 
lack of ethnic effects on treatment response. Although more than 90% of the 18 reviewed studies 
considered ethnicity in the analyses, no study found significant effects of ethnicity on outcome. 
However, Strada et al. found that only 6% of the studies had sufficient power to detect such 
effects. Hence, a second limitation of prior research has been insufficient sample sizes to test for 
ethnicity effects in treatment outcome. 
 
A third limitation of prior studies is failure to consider variables that might interact with ethnicity 
to affect outcome, such as comorbid psychopathology, gender, and age. Comorbid 
psychopathology has been associated with greater severity of substance use disorders and worse 
substance use outcomes (Brown et al., 1994, Grella et al., 2001 and Tims et al., 2002), and in at 
least one study, comorbidity has varied by ethnic group (Rounds-Bryant & Staab, 2001). Age 
and gender are also important variables to consider because older adolescents and males 
generally have higher rates of alcohol or illicit substance use than younger adolescents and 
females (Johnston et al., 2008). Finally, comorbidity may vary as a function of age and/or gender 
among substance-abusing adolescents, as the prevalence of common comorbid disorders is 
related to these variables (Lewinsohn et al., 1993 and Roberts et al., 2007). Thus, it is important 
to consider the effects of gender, age, and comorbidity when evaluating ethnic effects on ASA 
treatment outcomes. 
 
In this study, we address the aforementioned limitations by investigating baseline and 
posttreatment differences in a large, national sample of White, African American, and Latino 
youth, all of whom received the same evidence-based outpatient treatment for ASA. We also 
investigated baseline differences in comorbidity across the three groups and tested whether 
gender, age, or comorbidity predict or interact with ethnicity to affect treatment outcome. The 
context for this study was the multisite Effective Adolescent Treatment (EAT) project, which 
aimed to broadly disseminate an outpatient treatment for ASA that had prior evidence of 
effectiveness (SAMHSA, 2003). The treatment was Motivational Enhancement 
Therapy/Cognitive Behavior Therapy 5 Sessions (MET/CBT-5). In the Cannabis Youth 
Treatment study, MET/CBT-5 demonstrated comparable effectiveness to four more intensive 
treatments among 600 adolescents with cannabis abuse or dependence (Dennis, Godley, et al., 
2004). 
 
Our analysis was guided by two hypotheses. First, we expected that there would be ethnic 
differences in substance use and comorbid psychopathology at baseline. Specifically, we 
predicted that substance frequency would be higher in Whites and Latinos than in African 
Americans but that substance-related problems would be greater in African Americans than in 
Whites or Latinos. We also expected that rates of comorbid psychopathology at baseline would 
be higher in Whites, as compared with African Americans or Latinos. Second, we hypothesized 
that any ethnic group differences in substance use outcomes would be accounted for by baseline 
differences in substance frequency, substance-related problems, or comorbidity. Because age and 
gender have been associated with substance use and comorbidity, we explored potential effects 
of these variables in all analyses. 
 
2. Materials and methods 
2.1. Participants 
Participants in this study were adolescents (aged 13 through 18 years) who participated in the 
EAT dissemination project (SAMHSA, 2003). Inclusion criteria were as follows: (a) presenting 
problem of cannabis or alcohol use and (b) suitable for outpatient care by the American Society 
for Addiction Medicine criteria (Mee-Lee, Shulman, Fishman, Gastfriend, & Griffith, 2001). 
There were no other exclusion criteria to maximize opportunity for participation. Inclusion 
criteria were assessed in a structured interview (described in Measures). Participants were 
permitted to receive concurrent care for comorbid conditions, such as psychotropic medication 
for psychiatric disorders, but were asked to refrain from concurrent treatment for ASA. The 
project also included young adults, aged 19 to 21 years, but we restricted this study to 
adolescents to avoid confounds associated with increased drinking during the college years 
(SAMHSA, 2008) and to relate our findings to other ASA treatment studies. The EAT 
coordinating center at Chestnut Health Systems provided the multisite database for this study, 
which included 4,947 adolescents who were recruited across 36 sites. 
 
To test our hypotheses, we restricted the sample to those reporting White, African American, or 
Latino ethnic identity, resulting in the exclusion of 144 adolescents. We also excluded 
adolescents for whom no ethnic identification was denoted (n = 287) and for whom baseline 
comorbidity measures were missing (n = 14). Our final sample, therefore, included 4,502 
adolescents. Participants were predominantly male (71%), with a mean age of 15.62 years (SD = 
1.33 years). Ethnic composition was 59% White, 29% Latino, and 12% African American. 
Thirty-nine percent of the sample met diagnostic criteria for substance abuse, 38% met for 
dependence, and the remaining 21% reported substance problems that did not meet full criteria 
for abuse or dependence (American Psychiatric Association, 2000). 
 
2.2. Sites 
The 36 participating sites were geographically and ethnically diverse. Percentage of White 
adolescents ranged from 2.4% to 97.3% across the sites (M = 55.79%, SD = 27.27%). Percentage 
of African American teens ranged from 0% to 37% (M = 12.58%, SD = 11.74%), and percentage 
of Latino teens ranged from 1% to 97.6% (M = 29.38%, SD = 26.53%). The 36 sites covered 22 
states and the District of Columbia. Of the sites, 11 were in the Northeast, 7 in the South, 5 in the 
Midwest, and 13 in the West. 
 
2.3. Measures 
The core assessment measure in the EAT project was the Global Appraisal of Individual Needs 
Version 5 (GAIN; Dennis, White, Titus, & Unsicker, 2008), a standardized, structured interview 
with the adolescent. The GAIN has been normalized on both adolescents and adults and is one of 
the most widely used measures in ASA treatment studies in the United States (Dennis, Dawud-
Noursi, Muck, & McDermeit, 2003). A cross-validation of the GAIN alcohol and cannabis use 
measures with the Form 90 Timeline Followback indicated excellent comparability (r = .70–.80; 
Dennis, Funk, Godley, Godley, & Waldron, 2004). 
 
The GAIN spans eight domains, of which three were used in this study: background, substance 
use, and mental health. The GAIN was administered by trained, nationally certified interviewers 
at baseline and at 3, 6, and 12 months postbaseline. To assess acute treatment response, we 
focused on the 3-month assessment. 
 
2.3.1. Background items 
Participants' age in years, gender, and ethnic identity were assessed on specific items in the 
GAIN's background section. Ethnic identity was based on adolescent responses to the question 
“which races, ethnicities, nationalities, or tribes best describe you?” 
 
2.3.2. Comorbidity 
Internalizing comorbidity was assessed with the GAIN Internal Mental Distress Scale (IMDS). 
The IMDS has 43 items measuring symptoms experienced over the past 12 months, including 
depression, anxiety, traumatic stress, and suicidal ideation. Scores range from 0 to 43, with 
higher scores indicating more symptoms. The IMDS has demonstrated high internal consistency 
(α = .94; Dennis et al., 2008) and diagnostic validity for depressive disorders (κ = .85; Shane, 
Jasiukaitis, & Green, 2003). 
 
Externalizing comorbidity was assessed with the GAIN Behavior Complexity Scale (BCS). The 
BCS has 33 items measuring inattention, hyperactivity, and conduct problems experienced 
during the past 12 months. Scores range from 0 to 33, with higher scores indicating a higher 
level of symptoms. The BCS has exhibited high internal consistency (α = 91; Dennis et al., 2008) 
and diagnostic validity for attention-deficit/hyperactivity disorder (κ = 1.00) and for oppositional 
or conduct disorder (κ = 0.82; Shane et al., 2003). 
 
2.3.3. Substance use frequency 
The GAIN Substance Frequency Scale (SFS) is an eight-item scale that calculates the percentage 
of the past 90 days that the adolescent used alcohol or other drugs (excluding nicotine), with 
weighting for days of heavy use and crack/cocaine or heroin use. Scores range from 0 to 1, with 
higher scores indicating a greater percentage of heavy use days. The SFS has demonstrated 
internal consistency (α = .74), test–retest reliability, and evidence of construct and predictive 
validity ( Dennis et al., 2008 and Lennox et al., 2006). In the current sample, internal consistency 
was consistent with prior adolescent studies and comparable across ethnic groups: .76 for 
Whites, .72 for African Americans, and .75 for Latinos. 
 
2.3.4. Substance-related problems 
The GAIN Substance Problems Scale (SPS) is a 16-item scale that assesses the prevalence of 
problems associated with substance abuse or dependence over the past 30 days. The SPS 
includes symptoms of abuse and dependence and substance-related physical health, 
psychological, and interpersonal problems. Scores range from 0 to 16, with higher scores 
reflecting more problems. It has shown high internal consistency (α = .90) and test–retest 
reliability (r = .70; Dennis et al., 2002 and Dennis et al., 2008). Internal consistency in this 
sample was .87 for Whites, .85 for African Americans, and .87 for Latinos. 
 
2.4. Treatment 
The intervention was MET/CBT-5 (Sampl & Kadden, 2001), which combined two sessions of 
MET with three sessions of CBT. The two MET sessions focused on helping the adolescents to 
resolve ambivalence regarding their substance use and enhance motivation to change. In the CBT 
sessions, the focus changed to building drug or alcohol refusal, social support seeking, and 
relapse-prevention skills. Sessions were 60 minutes long. Anticipated treatment duration was 6 to 
7 weeks, but therapists could extend the duration to include all sessions. Treatment was delivered 
across a range of settings, including clinics, community mental health centers, and schools. 
Therapists were generally master's-level clinicians, social workers, or substance use counselors. 
 
2.5. Therapist training 
Therapists were trained using a train-the-trainers model. Each site designated one or more local 
MET/CBT-5 supervisors who were trained by expert clinicians in 3-day workshops. Supervisors 
then submitted audiotapes of one MET and one CBT session to national supervisors, which had 
to meet criteria for adherence and competence to proceed. Next, both local supervisors and the 
national supervisors independently rated audiotapes of sessions conducted by local therapists to 
determine the local supervisor's proficiency in approving and supervising site therapists. The 
local therapists needed to be rated as adherent and competent on a full set of MET/CBT-5 
sessions to obtain certification. Local supervisors met weekly with local therapists to monitor 
adherence and competence and participated in cross-site conference calls with national 
supervisors to address implementation and clinical issues across sites. 
 
2.6. Data analysis plan 
Prior to testing the two hypotheses, descriptive statistics were generated by ethnic group, and 
baseline correlations among the study variables were calculated. In addition, gender and age 
differences in the outcome variables (e.g., substance frequency, problems, and comorbidity) were 
examined. These analyses helped to determine which variables should be retained as covariates. 
 
To test the hypothesis of ethnic differences at baseline, we conducted hierarchical linear 
modeling (HLM) analyses to account for the nesting of participants within sites. All 4,502 
participants were included in these analyses. Demographic predictors (gender, age, and ethnicity) 
were modeled at Level 1, with random intercepts modeled at Level 2 to parcel out site effects. 
Variability due to site was calculated using an intraclass correlation coefficient. Age was split, 
with ages 13 to 15 years (45%) comprising the younger group and ages 16 to 18 years (55%) 
comprising the older group. All models were estimated in Proc Mixed in SAS 8.0, using 
restricted likelihood estimation and the between-within method to calculate degrees of freedom. 
In each model, ethnicity was dummy coded, and two analyses were run: one with Whites as the 
reference group and another with Latinos as the reference group. Additional HLM models 
examined whether age or gender significantly interacted with ethnicity to predict baseline 
substance use or comorbidity. 
 
Comparisons of assessment completers with noncompleters were conducted using multivariate 
analysis of variance (MANOVA) and chi-square. To test the hypothesis that any ethnic 
differences in outcomes would be attributable to baseline differences, we conducted two-step 
HLM analyses. Because imputation of posttreatment substance use outcomes was not justified 
with two time points, only those adolescents who completed the posttreatment assessment were 
included in these analyses. In Step 1 of the HLM, demographic predictors (age, gender, and 
ethnicity) were entered at Level 1, along with a variable indicating the number of MET/CBT-5 
sessions received. Site was entered as a random effect at Level 2. In Step 2, baseline values of 
the substance use and comorbidity variables were entered to determine if they accounted for any 
effects of the demographic predictors observed in the first step. Additional HLM models 
examined whether age, gender, or comorbid psychopathology significantly interacted with 
ethnicity to predict substance use frequency or problems. 
 
3. Results 
3.1. Preliminary analyses 
Baseline sample characteristics by ethnic group, prior to adjustments for site differences, are 
depicted in Table 1. Relative to the other groups, the White group contained a greater proportion 
of females and older adolescents. African American adolescents had lower levels of dependence 
diagnoses and comorbid mental health diagnoses than White or Latino adolescents. 
Table 1. Baseline sample characteristics by ethnic group (N = 4,502) 
Characteristic White Latino African American F/χ2 
Sample size, n (%) 2,670 (59) 1,282 (28) 550 (13)  
Female 58 49 52 20.63⁎ 
Age    15.07⁎ 
 13–15 years 42 51 48  
 16–18 years 58 49 52  
Substance diagnoses     
 Abuse 39 40 39 0.74 
 Dependence 40 25 42 24.88⁎ 
Comorbid diagnoses     
 Depression 31 20 30 14.01⁎ 
 Generalized anxiety 9 4 10 8.87⁎ 
 Traumatic stress 19 12 22 11.97⁎ 
 Conduct disorder 45 34 47 14.33⁎ 
 ADHD 46 23 39 50.85⁎ 
Note. Values are percentages unless otherwise indicated. ADHD = attention-deficit/hyperactivity 
disorder. 
 
⁎ p < .001 
Table 2 depicts baseline correlations among the study variables. The two ASA measures 
(frequency and problems) were highly correlated with one another, as were the two measures of 
comorbidity (internalizing and externalizing). Measures of ASA were moderately correlated with 
measures of comorbidity. T tests by age indicated that older adolescents reported higher 
substance frequency, t(4,500) = −4.32, p < .001, whereas younger adolescents had higher levels 
of internalizing, t(4,500) = 2.23, p =.03, and externalizing, t(4,500) = 5.53, p < .001, 
comorbidity. T tests by gender indicated that girls had more substance problems, more 
internalizing symptoms and more externalizing symptoms than boys, t(4,500) = 3.40, 23.05, 
10.16; all p values < .001. These results, as well as the group differences in Table 1, reinforced 
the need to retain gender, age, and comorbid psychopathology as covariates. 
Table 2. Means, standard deviations, and correlations of outcome variables at baseline (N = 
4,502) 
Variable 2 3 4 M SD 
1. SFS 0.60⁎ 0.27⁎ 0.29⁎ 0.11 0.13 
2. SPS  0.35⁎ 0.34⁎ 2.72 3.37 
3. IMDS   0.59⁎ 7.39 8.14 
4. BCS    9.57 7.88 
Note. SFS, possible range = 0–1; SPS, possible range = 0–16; IMDS, possible range = 0–43; 
BCS, possible range = 0–33. 
⁎ p < .001. 
3.2. Ethnic differences at entry into treatment 
3.2.1. Substance use frequency 
The HLM including SFS as the criterion indicated gender, age, and ethnicity effects at baseline. 
Site accounted for 9% of the variance in SFS. Girls and older adolescents reported more frequent 
use (for gender, B = −0.01, p = .02; for age, B = 0.02, p < .001). Consistent with our hypothesis, 
African American adolescents reported less frequent use than Whites (B = −0.01, p = .02) or 
Latinos (B = −0.01, p = .02). No differences were found between White and Latino youth. There 
were no significant interactions of age or gender with ethnicity. 
 
3.2.2. Substance-related problems 
The HLM with SPS as the criterion indicated gender and ethnicity effects. Site accounted for 8% 
of the variance. Girls reported more problems than boys (B = −0.52, p < .001). Counter to our 
hypothesis, African American teens reported fewer problems than Whites (B = −0.39, p = .01) or 
Latinos (B = −0.42, p = .02). White and Latino youth did not significantly differ. There were no 
significant interactions of age or gender with ethnicity. 
 
3.2.3. Internalizing comorbidity 
With IMDS as the criterion, site accounted for 9% of the variance. The HLM revealed gender 
and ethnicity effects. Girls reported more internalizing symptoms than boys (B = −5.55, p < 
.001). African American teens reported fewer symptoms than Whites (B = −1.10, p < .01) or 
Latinos (B = −1.57, p < .001). Again, White and Latino youth did not differ. There were no 
significant interactions of age or gender with ethnicity. 
 
3.2.4. Externalizing comorbidity 
With BCS as the criterion, site accounted for 8% of the variance. The HLM revealed effects for 
gender, age, and ethnicity. Girls had more externalizing problems than boys (B = −2.16, p < 
.001); younger adolescents had more problems than older adolescents (B = −1.22, p < .001); and 
African Americans had fewer problems than White (B = −2.06, p < .001) or Latinos (B = −1.76, 
p < .001). White and Latino teens did not differ. There were no significant interactions of age or 
gender with ethnicity on externalizing comorbidity. 
 
3.3. Ethnic differences at posttreatment assessment 
3.3.1. Comparison of completers versus noncompleters 
Of those entering the EAT project, 3,184 (71%) completed the 3-month assessment and were 
included in the posttreatment analyses. A MANOVA comparing assessment completers and 
noncompleters on the two baseline measures of substance use and the two baseline measures of 
comorbidity was not significant, F(4, 4,497) = 1.64, p = .16. However, chi-square tests indicated 
that assessment completion was associated with all three demographic variables. Assessment 
completion was more likely among females than males (75% vs. 69%), χ2(1, N = 4,502) = 
13.09, p < .001, and among younger adolescents than older adolescents (74% vs. 68%), χ
2(1, N = 4,502) 15.97, p < .001. In addition, African American teens (63%) were less likely to 
complete the assessment than White teens (73%), χ2(1, N = 4,502) = 21.33, p < .001, or Latino 
teens (70%),χ2(1, N = 4,502) = 7.22, p < .01. Thus, the following results are only relevant to 
assessment completers. 
Mean SFS and SPS scores were significantly lower at 3 months than at baseline for all three 
ethnic groups (pvalues < .001). Using Cohen's d (1988), effect sizes of the change were .39 to 
.45 for substance frequency and .30 to .39 for substance problems, indicating that all three 
groups experienced medium-sized reductions in substance frequency and problems. 
A one-way analysis of variance indicated significant differences in the number of treatment 
sessions received by ethnic group, F(2, 3,182) = 34.21, p < .001. Comparisons using Tukey's 
post-hoc test revealed that White teens received significantly more sessions (M = 3.5, SD = 2.5) 
than African American s (M = 2.7,SD = 2.6) or Latinos (M = 2.8, SD = 2.7). These data 
underscored the need to control for number of MET/CBT-5 sessions in the posttreatment HLM. 
3.3.2. Substance use frequency 
When only demographic variables (gender, age, and ethnicity) and number of treatment sessions 
were entered into the HLM with 3-month SFS as the criterion, there were ethnic and age effects. 
African American teens demonstrated lower SFS scores than Latinos (B = −0.02, p = .02). 
Whites did not differ from Latinos or African Americans. In addition, older adolescents had 
higher SFS scores than younger adolescents (B = .01, p = .01). 
 
Consistent with our hypothesis, the posttreatment ethnic differences were no longer significant 
when controlling for baseline SFS and comorbidity. Site differences dropped to 2%. As shown in 
Table 3, higher 3-month SFS scores were significantly predicted by baseline SFS (B = 0.39, p < 
.001) and externalizing symptoms (B = 0.001, p = .02). In addition, males had higher 3-month 
SFS scores than females (B = 0.01, p = .02). Further HLM models revealed no significant 
interactions of ethnicity with gender, age, or comorbid psychopathology on 3-month SFS scores. 
Table 3. Predictors of substance use frequency posttreatment with Latino youth as reference 
group (n = 3,181) 
Predictor B SE t p 
Intercept −0.01 0.01 0.76 .46 
African American −0.01 0.01 −1.18 .24 
White −0.01 0.00 −1.54 .12 
Age 0.00 0.00 1.46 .14 
Predictor B SE t p 
Gender 0.01 0.00 2.37 .02 
No. of sessions −0.00 0.00 −0.74 .46 
Baseline SFS 0.39 0.01 28.15 <.001 
Baseline BCS 0.00 0.00 2.23 .03 
Baseline IMDS 0.00 0.00 1.35 .18 
Note. The same pattern of results was observed with White youth as the reference group. 
3.3.3. Substance-related problems 
When demographic predictors (gender, age, and ethnicity) and number of sessions were entered 
into the HLM with 3-month SPS as the criterion, there were effects of ethnicity and number of 
sessions received. Site accounted for 5% of the variance. African American teens demonstrated 
significantly lower SPS scores compared with White teens (B = −0.40, p = .02) but did not differ 
from Latino youth. Across all adolescents, more treatment sessions were associated with higher 
SPS scores (B = 0.06, p = .02). 
 
Consistent with our hypothesis, ethnic differences in the 3-month SPS were no longer significant 
when controlling for baseline SPS and comorbidity. Site differences dropped to 2%. As indicated 
in Table 4, SPS scores at 3 months were significantly predicted by greater baseline SPS (B = 
0.28, p < .001), externalizing symptoms (B = 0.04, p < .001), internalizing symptoms (B = 0.02, 
p = .03), and more treatment sessions (B = 0.06, p < .01). In addition, males had higher 3-month 
SPS scores than females (B = 0.30, p < .01). Further, HLM models found no significant 
interaction effects of gender, age, or comorbid psychopathology with ethnicity. 
Table 4. Predictors of substance-related problems posttreatment with White youth as reference 
group (n = 3,178) 
Predictor B SE t p 
Intercept −0.31 0.22 −1.38 .18 
African American −0.15 0.16 −0.95 .34 
Latino 0.05 0.12 0.44 .66 
Age 0.19 0.10 1.90 .06 
Predictor B SE t p 
Gender 0.30 0.11 2.71 <.01 
No. of sessions 0.06 0.02 2.90 <.01 
Baseline SPS 0.28 0.02 17.66 <.001 
Baseline BCS 0.04 0.01 5.46 <.001 
Baseline IMDS 0.02 0.01 2.22 .03 
Note. The same pattern of results was observed with Latino youth as the reference group. 
4. Discussion 
This study evaluated the effectiveness of a brief evidence-based intervention for ASA across 
three ethnic groups (Whites, Latinos, and African Americans) while controlling for four putative 
covariates (e.g., age, gender, internalizing comorbidity, externalizing comorbidity). In this large 
national sample, we found significant ethnic differences at baseline. Consistent with prior 
literature and our first hypothesis, African American adolescents began treatment with lower 
frequency of substance use than did White or Latino teens. Moreover, African American youth 
presented with fewer substance-related problems, internalizing symptoms, and externalizing 
symptoms. These findings are internally consistent, although our finding that African Americans 
had fewer substance-related problems was counter to our hypothesis. Prior studies documenting 
elevated substance-related problems among African American teens relative to Whites (e.g., 
Godette et al., 2006 and Maag and Irvin, 2005) have often focused on alcohol-related problems. 
The fact that African Americans in this sample had fewer substance problems may reflect our 
broader inclusion of teens with problematic alcohol and/or cannabis use. 
 
At baseline, our two putative covariates—age and gender—were both related to indices of ASA 
and comorbid psychopathology. Girls entering treatment had significantly higher scores than 
boys on measures of substance use frequency, substance-related problems, and internalizing and 
externalizing symptoms. Our findings are consistent with those of Stevens, Estrada, Murphy, 
McKnight, and Tims (2004), who compared 941 males and 266 females in seven treatment 
programs. In their study, females had greater baseline severity in substance use, substance-
related problems, and mental health problems. These results may reflect a generalized 
vulnerability among females who abuse substances, or a treatment-seeking effect whereby girls 
are less likely to enter or be referred to ASA treatment until their problems are more severe. 
 
Age differences at baseline were somewhat less consistent. Substance use frequency was higher 
among older teens, congruent with epidemiological surveys (Wallace et al., 2003). By contrast, 
externalizing symptoms were higher in younger teens. Our findings suggest that older teens may 
present with a more “pure” form of substance use disorders, whereas younger teens may present 
with substance use in the context of attentional and/or behavioral problems. 
 
Among adolescents who completed the posttreatment assessment (71%), there were again ethnic 
differences, but consistent with our second hypothesis, these differences were attributable to 
baseline differences. With all of our putative covariates entered into the model, baseline 
substance use frequency and comorbid externalizing psychopathology, but not ethnicity, 
predicted substance use frequency after treatment. In a similar analysis, baseline substance-
related problems, comorbid internalizing and externalizing symptoms, and amount of treatment 
received, but not ethnicity, predicted substance-related problems after treatment. This lack of 
ethnic differences in treatment outcome is similar to the findings of Rounds-Bryant and Staab 
(2001) from the DATOS-A project and those of Strada et al. (2006) in their review of ASA 
treatment studies. Results are also consistent with a recent multisite implementation study by 
Godley, Hedges, and Hunter (2011), which found that White, African American, and Latino 
youth had equivalent initiation, engagement, and treatment outcomes following an evidence-
based outpatient intervention. Although we cannot disregard the possibility that differential 
completion of the posttreatment assessment contributes to these findings (discussed further 
below), our results are bolstered by the large sample size, as well as the consistency with prior 
investigations. 
 
The posttreatment analysis also indicated significant, independent effects of gender and 
comorbidity, highlighting the importance of including these covariates in analyses of ethnic 
differences. At the posttreatment assessment, males had poorer outcomes than females, despite 
having entered the project with more favorable baseline scores. In addition, teens with more 
internalizing symptoms had more substance-related problems following treatment, whereas teens 
with more externalizing symptoms had higher substance frequency and problems. The effects of 
comorbidity on posttreatment outcome were small, particularly for internalizing symptoms. Our 
findings on gender and comorbidity are consistent with previous studies. In one study, Harrison 
and Asche (2001) studied 387 adolescents in 37 programs and found that females were more 
likely than males to complete treatment and to be abstinent from drug use after treatment. In 
another study, Hsieh and Hollister (2004) studied more than 2,000 adolescents and found that 
females had more psychological difficulties than males but had better treatment attendance and 
better outcomes. Finally, several studies have documented an association between comorbid 
psychopathology and substance use severity both at baseline and posttreatment (Grella et al., 
2001, Tomlinson et al., 2004 and Winters et al., 2008). 
 
4.1. Limitations 
The primary limitation of this study is that the outcome findings are restricted to adolescents who 
completed the posttreatment assessment: 71% of the total sample. It is critical to note that 
assessment completion is not identical to treatment completion. Among assessment completers, 
adolescents received an average of 3.4 sessions (SD = 2.5), demonstrating that many adolescents 
who did not complete all five treatment sessions remained in the assessment protocol. The EAT 
project continued to collect data from those adolescents who dropped out of treatment and who 
participated in assessments. However, because of the EAT project's emphasis on treatment 
dissemination, limited data were collected from those adolescents who did not complete 
assessments. The multisite database did not systematically track reasons for withdrawal or the 
number of sessions completed by youth who dropped out of the research protocol. Thus, we 
cannot generalize findings to youth who either dropped out of the project or who completed 
treatment but not the subsequent assessment. 
 
Assessment completers were more likely to be young adolescents, females, and either White or 
Latino. Further research is needed to understand whether greater dropout among African 
American youth is attributable to limited cultural sensitivity, poor engagement strategies, or 
differential effectiveness of early treatment. It is encouraging that teens who did not complete the 
assessment did not differ from completers at baseline on the two substance use outcomes or two 
mental health outcomes that were the focus of this analysis. Moreover, the large proportion of 
African American youth who completed the assessment experienced equivalent treatment benefit 
to White and Latino youth, despite receiving fewer sessions. Indeed, receipt of more treatment 
sessions was associated with more substance problems at 3 months, suggesting that the full 
treatment may not have been deemed as necessary by teens with fewer substance problems. 
 
This study has several other limitations. First, the EAT project aimed to disseminate a single 
evidence-based brief intervention and did not include a control or comparison condition. 
Although we controlled for the number of sessions received, outcomes cannot be attributed 
specifically to the intervention. Second, it is possible that the brevity of the treatment may have 
limited our ability to detect differences in outcome. This limitation is tempered by the fact that 
all three ethnicities had significant, medium-sized reductions in substance frequency and 
problems. Third, among the variables not included in the EAT database was socioeconomic 
status (SES), which is often related to ethnicity and therefore may contribute to the observed 
effects of ethnic status on substance use. Moreover, this analysis intentionally focused on four 
putative covariates and did not consider other variables that might be associated with ethnicity, 
such as family composition, criminal justice involvement, level of acculturation, country of 
origin, and foreign- versus American-born status (Godley et al., 2011, Wallace et al., 2002 and 
Wallace et al., 2003). Given the lack of ethnic effects on posttreatment outcome, confounding 
effects of SES and other covariates are somewhat less of a concern in this study. 
 
4.2. Implications 
Results of this study indicate that MET/CBT-5 did not differ in effectiveness across a large 
sample of White, African American, and Latino youth who completed the posttreatment 
assessment. Although encouraging, we cannot conclude that these results would have held up if 
the proportion of outcome data were equivalent across ethnic groups. These findings have two 
major implications for clinical practice and effectiveness research. First, our results argue for the 
applicability of MET/CBT-5 among adolescents and add to the growing body of literature 
suggesting that evidence-based treatments may not require significant adaptations to be effective 
across ethnic groups. Second, and as a caveat to the first, our findings demonstrate that 
differential retention in research needs to be addressed proactively in the evaluation of evidence-
based practice. Specifically, our data suggest that culturally sensitive strategies may be needed to 
retain African Americans in research. More generally, this study underscores the need for 
effectiveness researchers to use comprehensive follow-up strategies to retain all participants in 
the assessment protocol and to systematically track reasons for dropout. 
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